People

Oliver Eng, MD

Response to the Comment on "Cancer Surgery During COVID-19: How We Move Forward".
Eng OS, Pawlik TM, Ejaz A. Response to the Comment on "Cancer Surgery During COVID-19: How We Move Forward". Ann Surg. 2021 12 01; 274(6):e828-e829.
PMID: 33214441

ASO Author Reflections: Disparities in Access to Cytoreductive Surgery.
Goldberg EM, Eng OS. ASO Author Reflections: Disparities in Access to Cytoreductive Surgery. Ann Surg Oncol. 2021 11; 28(12):7807-7808.
PMID: 34013481

Response to Comment on "Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy".
White MG, Eng OS. Response to Comment on "Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy". Br J Cancer. 2021 03; 124(6):1179-1180.
PMID: 33318658

A multi-institutional analysis of Textbook Outcomes among patients undergoing cytoreductive surgery for peritoneal surface malignancies.
Wiseman JT, Abdel-Misih S, Beal EW, Zaidi MY, Staley CA, Grotz T, Leiting J, Fournier K, Lee AJ, Dineen S, Powers B, Veerapong J, Baumgartner JM, Clarke C, Patel SH, Dhar V, Hendrix RJ, Lambert L, Abbott DE, Pokrzywa C, Raoof M, Eng O, Fackche N, Greer J, Pawlik TM, Cloyd JM. A multi-institutional analysis of Textbook Outcomes among patients undergoing cytoreductive surgery for peritoneal surface malignancies. Surg Oncol. 2021 Jun; 37:101492.
PMID: 33465587

Response to: Comment on "Cancer Surgery During COVID-19 How We Move Forward".
Eng OS, Pawlik TM, Ejaz A. Response to: Comment on "Cancer Surgery During COVID-19 How We Move Forward". Ann Surg. 2020 Nov 17.
PMID: 33214441

Cancer Surgery During COVID-19: How We Move Forward.
Eng OS, Pawlik TM, Ejaz A. Cancer Surgery During COVID-19: How We Move Forward. Ann Surg. 2020 08; 272(2):e94-e95.
PMID: 32675508

Implications of Postoperative Complications for Survival After Cytoreductive Surgery and HIPEC: A Multi-Institutional Analysis of the US HIPEC Collaborative.
Gamboa AC, Lee RM, Turgeon MK, Zaidi MY, Kimbrough CW, Grotz TE, Leiting J, Fournier K, Lee AJ, Dineen SP, Powers BD, Veerapong J, Baumgartner JM, Clarke CN, Mogal H, Patel SH, Lee TC, Lambert LA, Hendrix RJ, Abbott DE, Pokrzywa C, Raoof M, Eng OS, Johnston FM, Greer J, Cloyd JM, Maithel SK, Staley CA. Implications of Postoperative Complications for Survival After Cytoreductive Surgery and HIPEC: A Multi-Institutional Analysis of the US HIPEC Collaborative. Ann Surg Oncol. 2020 Dec; 27(13):4980-4995.
PMID: 32696303

Institutional variation in recovery after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: An opportunity for enhanced recovery pathways.
Eng OS, Blakely AM, Lafaro KJ, Fournier KF, Fackche NT, Johnston FM, Dineen S, Powers B, Hendrix R, Lambert LA, Ronnekleiv-Kelly S, Walle KV, Grotz TE, Leiting JL, Patel SH, Dhar VK, Baumgartner JM, Lowy AM, Clarke CN, Mogal H, Zaidi MY, Staley CA, Kimbrough C, Cloyd JM, Lee B, Raoof M. Institutional variation in recovery after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: An opportunity for enhanced recovery pathways. J Surg Oncol. 2020 Oct; 122(5):980-985.
PMID: 32627199

Cancer Surgery During COVID-19: How We Move Forward.
Eng OS, Pawlik TM, Ejaz A. Cancer Surgery During COVID-19: How We Move Forward. Ann Surg. 2020 May 20.
PMID: 32433289

Virtual Surgical Fellowship Recruitment During COVID-19 and Its Implications for Resident/Fellow Recruitment in the Future.
Vining CC, Eng OS, Hogg ME, Schuitevoerder D, Silverman RS, Yao KA, Winchester DJ, Roggin KK, Talamonti MS, Posner MC, Turaga KK, Tseng J. Virtual Surgical Fellowship Recruitment During COVID-19 and Its Implications for Resident/Fellow Recruitment in the Future. Ann Surg Oncol. 2020 May 18; 1-5.
PMID: 32425476

View All Publications